ArticlePharmaceutics2021
Reprogramming Extracellular Vesicles for Protein Therapeutics Delivery.
Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Production of Genetically Engineered Extracellular Vesicles for Targeted Protein Delivery.Bio-protocol · 2025Article
- Droplet Squeeze Microfluidic Platform for Generating Extracellular Vesicle Hybrids for Drug Delivery.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Protective Effects of Rat Bone Marrow Mesenchymal Stem Cells-Derived Fusogenic Plasma Membrane Vesicles Containing VSVG Protein Mediated Mitochondrial Transfer on Myocardial Injury In Vitro.FASEB bioAdvances · 2025Article
- Targeted macrophage mannose receptor (CD206)-specific protein delivery via engineered extracellular vesicles.Heliyon · 2024Article
- Engineering exosomes derived from TNF-α preconditioned IPFP-MSCs enhance both yield and therapeutic efficacy for osteoarthritis.Journal of nanobiotechnology · 2024Article
- Harnessing genetically engineered cell membrane-derived vesicles as biotherapeutics.Extracellular vesicles and circulating nucleic acids · 2024Review
- Characterizing the extracellular vesicle proteomic landscape of the human airway usingiScience · 2023Article
- Magnetic and Fluorescent Dual-Labeled Genetically Encoded Targeted Nanoparticles for Malignant Glioma Cell Tracking and Drug Delivery.Pharmaceutics · 2023Article
- Polymers in Engineering Extracellular Vesicle Mimetics: Current Status and Prospective.Pharmaceutics · 2023Review
- Extracellular vesicles and COPD: foe or friend?Journal of nanobiotechnology · 2023Review
- Cell-derived nanovesicle-mediated drug delivery to the brain: Principles and strategies for vesicle engineering.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Review
- Advances in Extracellular Vesicle Nanotechnology for Precision Theranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Current Knowledge and Future Perspectives of Exosomes as Nanocarriers in Diagnosis and Treatment of Diseases.International journal of nanomedicine · 2023Review
- Extracellular Vesicles in Chronic Demyelinating Diseases: Prospects in Treatment and Diagnosis of Autoimmune Neurological Disorders.Life (Basel, Switzerland) · 2022Review
- The updated role of exosomal proteins in the diagnosis, prognosis, and treatment of cancer.Experimental & molecular medicine · 2022Review
- Application of engineered extracellular vesicles for targeted tumor therapy.Journal of biomedical science · 2022Review
- Protective role of engineered extracellular vesicles loaded quercetin nanoparticles as anti-viral therapy against SARS-CoV-2 infection: A prospective review.Frontiers in immunology · 2022Review
- Extracellular Vesicles as Therapeutic Tools for the Treatment of Chronic Wounds.Pharmaceutics · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Delivering protein therapeutics specifically into target cells and tissues is a promising avenue in medicine. Advancing this process will significantly enhance the efficiency of the designed drugs. In this regard, natural membrane-based systems are of particular interest. Extracellular vesicles (EVs), being the bilayer lipid particles secreted by almost all types of cells, have several principal advantages: biocompatibility, carrier stability, and blood-brain barrier penetrability, which make them a perspective tool for protein therapeutic delivery. Here, we evaluate the engineered genetically encoded EVs produced by a human cell line, which allow efficient cargo loading. In the devised system, the protein of interest is captured by self-assembling structures, i.e., "enveloped protein nanocages" (EPN). In their turn, EPNs are encapsulated in fusogenic EVs by the overexpression of vesicular stomatitis virus G protein (VSV-G). The proteomic profiles of different engineered EVs were determined for a comprehensive evaluation of their therapeutic potential. EVs loading mediated by bio-safe Fos-Jun heterodimerization demonstrates an increased efficacy of active cargo loading and delivery into target cells. Our results emphasize the outstanding technological and biomedical potential of the engineered EV systems, including their application in adoptive cell transfer and targeted cell reprogramming.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.